Skip to main content
Skip to main navigation
Search for :
Product Development Strategy
Early Clinical Development
Phase I/IIa Clinical Trials
Phase II/III Clinical Trials
Interventional Phase IIIb/Phase IV Clinical Trials
Observational Research & Registries
Product Launch & Management
Market Access Solutions
Strategic Sales Outsourcing
Biopharmaceutical Sales & Marketing
Healthcare Payers & Providers
Medical Device & Diagnostics
Public Health & Government
Central Nervous System
Diabetes & Endocrinology
Early Phase Oncology
Public Health Interest
Other Therapeutic Areas
Ethics & Compliance
Press Release - April 4, 2012
By: Greg Connors - Phil Bridges
Select one of the options below to save this article to your library.
RESEARCH TRIANGLE PARK, NC – April 4, 2012 – Quintiles and the American Diabetes Association (Association) today announced a strategic agreement in which Quintiles’ Digital Patient Unit will provide the Association’s millions of website users access to Quintiles’ medication monitoring service.
The Association’s constituents who opt in for the service will receive free safety checks of their medications to identify potential interactions and other risk factors, which are already provided to the 2.5 million registered users of Quintiles’ www.MediGuard.org. Registrants will also be eligible to participate in select direct-to-patient programs to benefit their medical conditions and advance global diabetes patient care.
“We are very pleased to offer this medication monitoring service to improve the lives of all people affected by diabetes,” said Vivian Fonseca, MD, President, Medicine & Science, American Diabetes Association. “This collaboration with Quintiles enables the Association to provide important safety information at no cost to our constituents”.
The Association’s constituents may opt in to this service from the Association’s website www.Diabetes.org. All registrant data will reside on Quintiles’ privacy-safe, Digital Patient Platform. Quintiles’ Digital Patient Unit will manage the patient relationships from this platform, continuously providing up-to-date medication safety information and introducing members to direct-to-patient clinical research, observational studies and disease management opportunities.
Quintiles’ David Coman, Senior Vice President Communication and Patient Recruitment, echoed Dr. Fonseca’s sentiments. “This relationship between Quintiles and the American Diabetes Association illustrates the manner in which associations help promote better health outcomes for their members or constituents,” Coman said. “The very first pharma project undertaken by our founder involved a diabetes treatment, so it is fitting that we are innovating in this area once again on our 30-year anniversary."
Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. Our network of more than 25,000 professionals in 60 countries has an eye on the future while delivering results today with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies develop and commercialize products to improve and lengthen patients’ lives while demonstrating value to stakeholders. Visit www.quintiles.com for more information and www.quintiles.com/news for additional company news.
About Quintiles’ Digital Patient Unit
Quintiles’ Digital Patient Unit (DPU) was formed in January 2012 to provide patients with information to better manage their personal health and provide them with opportunities to participate in clinical research, observational studies and programs to better manage their conditions. At the core of the DPU is its privacy-safe community management platform, flagship communities www.MediGuard.org and www.ClinicalResearch.com and its global, clinically-profiled 2.7 million community members.